Age Restriction Update for Vyjuvek Procedure Code J3401
Date: January 26, 2026
Attention: All Providers
Effective date: March 1, 2026
Call to action: Texas Children’s Health Plan (TCHP) informs providers that effective for dates of service on or after March 1, 2026, the Food and Drug Administration (FDA) has approved an age expansion for beremagene geperpavec-svdt (Vyjuvek) procedure code J3401 to include adult and pediatric clients of all ages.
Next steps: Providers should share this communication with their staff.
If you have any questions, please email Provider Relations at: providerrelations@texaschildrens.org.
For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.